Phase II randomized trial of 3D radiotherapy versus the combination of 3D radiotherapy and erlotinib (Tarceva) in patients with localized-unresectable non-small cell lung cancer non susceptible for chemotherapy treatment

Trial Profile

Phase II randomized trial of 3D radiotherapy versus the combination of 3D radiotherapy and erlotinib (Tarceva) in patients with localized-unresectable non-small cell lung cancer non susceptible for chemotherapy treatment

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top